SILENCE THERAP. SP.ADR/1 (XRP2) — Cash Flow Reinvestment Rate
SILENCE THERAP. SP.ADR/1 (XRP2) has a Cash Flow Reinvestment Rate of 1.67x as of December 2021, reinvesting €15.30 Million (capex €1.80 Million plus investments €13.50 Million) from operating cash flow of €9.19 Million. Explore how efficiently does SILENCE THERAP. SP.ADR/1 generate cash to assess how effectively this company generates cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
SILENCE THERAP. SP.ADR/1 Cash Flow Reinvestment Rate (2021–2021)
Historical reinvestment intensity for SILENCE THERAP. SP.ADR/1 across 1 annual periods. Explore SILENCE THERAP. SP.ADR/1 long-term investment allocation to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for SILENCE THERAP. SP.ADR/1 (2021–2021)
Year-by-year capital reinvestment analysis for SILENCE THERAP. SP.ADR/1. For live market cap and broader valuation context, see XRP2 market cap overview.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 1.67x | €15.30 Million | €9.19 Million | €1.80 Million | — |